We're Not Trippin"

05/03/2026

Our Walk is Saturday the 16th, we are at $720, not quite halfway to goal. Hoping to crush it like we have the past few years. Every little bit helps as this goes to research and programs to help everyone affected by MS. I know gas is almost $5 a gallon and things are tight. Please share our link, NOTHING is to small, even a $5 donation when combined with others makes an impact! This is the only fundraiser we do, please share,share and share again.
Our goal is set at $2000 far below what we did the past few years.

Let's do this!!! This is not only for us but future generations coming down the line that have to deal with MS as well.

I’m raising money for the National MS Society and can use your help. Your support means more groundbreaking research, life-changing services and gets us one step closer to a cure! Together we can make a difference for those living with MS — donate today!

04/29/2026

There’s a side of MS that doesn’t show up on scans or symptom lists. It shows up in everyday moments, in the decisions you have to make, the pauses you didn’t plan for, and the emotions you carry. It’s the weight you feel when you have to slow down, when plans change at the last minute, or when fatigue takes over even though your mind is telling you to push through.

The guilt of all the "can'ts" might stack up, but know that you are not weak for needing rest, and you aren't letting anyone down by honoring your limits.

04/25/2026

04/25/2026

This is this years shirt design. Hope you like it, it is a bit different then the other years, but I think I like it best. Lots of meaning , in that outer circle of demylinated axons. Crown of thorns, circle of life, ring of fire...you decide

04/25/2026

Today marks a historic shift:
cannabis is being moved to Schedule III under the U.S. Drug Enforcement Administration.

This is progress—but let’s be clear—it’s not legalization.

The Pros:
✔️ Acknowledges medical value
✔️ Opens the door for real research
✔️ Eases crushing tax burdens (goodbye 280E)
✔️ Signals a shift in federal thinking

The Cons:
⚠️ Keeps cannabis federally controlled
⚠️ Could invite stricter oversight from the U.S. Food and Drug Administration
⚠️ Risks sidelining state-legal operators
⚠️ Leaves social equity issues unresolved

We’re entering a new phase—not the finish line. The question now is: who shapes what comes next?

— Montel

04/24/2026

So Facebook will no longer show people this page as a recommendation because I shared Montel Williams, an MS warrior celebrating 420 day. Guess they are unaware of the healing properties we have that come from the earth instead of pharma.

Oh well, we will do our own promoting and fit our treatments to our lifestyles and what is best for each and everyone of us, be if natural, pharma, or any combination thereof.

04/23/2026

04/23/2026

Here is our the link to our page for the MS Walk in Highland on May 16th. Even if you can't make it, consider donating something to our cause. The money earned helps every person touched by MS in some way.

I’m raising money for the National MS Society and can use your help. Your support means more groundbreaking research, life-changing services and gets us one step closer to a cure! Together we can make a difference for those living with MS — donate today!

03/23/2026

Come join us this Wednesday March 25th, 6PM, 521 E 86th Ave Merrillville, IN

03/22/2026

02/15/2026

Scientists say they have found a way to repair MS-related nerve damage — not just slow it down! A promising new class of drugs may offer a way to repair the nerve damage caused by multiple sclerosis (MS), which is something current treatments cannot do. In MS, the immune system attacks myelin, the protective layer that surrounds nerve fibers, leading to progressive disability. Now, researchers from UC Riverside and the University of Illinois have identified two compounds, K102 and K110, that not only regulate immune activity but also stimulate the body’s natural ability to rebuild myelin.

K102, the most promising candidate, promoted remyelination in both mouse models and human-derived cells in the lab, effectively restoring nerve insulation and function. These compounds work by activating oligodendrocyte precursor cells—the building blocks of myelin—and encouraging them to mature and repair damaged fibers. That process breaks down in MS, but K102 appears to reignite it. After screening over 60 molecular variants, scientists landed on these two drug-like compounds with strong safety and efficacy profiles. The research has now moved toward clinical development, licensed by biotech startup Cadenza Bio. While human trials are still ahead, this breakthrough may eventually offer new hope not just for MS patients, but for anyone suffering from conditions involving nerve damage, such as spinal cord injuries or stroke.